Prognose

Kaufen	0
Halten	0
Verkaufen	1

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	5 / 18
Levermann-Strategie	-2 / 13

News

EUROAPI moves into a new chapter with new Governance and Leadership
Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company's Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the recommendation of the Nominations and Compensation Committee, the Board has appointed Emmanuel Blin as Chair of the Board and David Seignolle as Chief Executive Officer, effective immediately. In response to the new governance, Elizabeth Bastoni stepped down as Independent Lead Director; she remains Chair of the Nominations and Compensation Committee. » Mehr auf globenewswire.com
Olivier Falut appointed EUROAPI's Chief Financial Officer
Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI's Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition.» Mehr auf globenewswire.com
EUROAPI closes the financing of its FOCUS-27 plan
Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing the financing of its FOCUS-27 strategic plan.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte EUROAPI einen Umsatz von 225,45 Mio€ und ein Nettoeinkommen von −17,40 Mio€

(EUR)	Juni 2024	YOY
Umsatz	+225,45 Mio	-
Bruttoeinkommen	+49,00 Mio	-
Nettoeinkommen	−17,40 Mio	-
EBITDA	+21,35 Mio	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+281,68 Mio€
Anzahl Aktien	95,26 Mio
52 Wochen-Hoch/Tief	+6,43€ - +2,67€
Dividenden	Nein
Beta	0,56
KGV (PE Ratio)	−0,71
KGWV (PEG Ratio)	+0,03
KBV (PB Ratio)	+0,33
KUV (PS Ratio)	+0,24

Unternehmensprofil

Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.